iiCON and the Liverpool School of Tropical Medicine: A partnership tackling emerging viral threats and neglected tropical diseases
A £2.7 million Translational Development Fund to support the development of new diagnostics and treatments.

Overview
The Translational Development Fund was launched in partnership with the Liverpool School of Tropical Medicine (LSTM) to support the development of diagnostics and treatments. We also joined the LSTM-led Infection Innovation Consortium (iiCON) to accelerate the discovery and development of new therapies and innovations.
About the Translational Development Fund
We are partnering with the Liverpool School of Tropical Medicine (LSTM) to launch a new £2.7 million Translational Development Fund. This fund will support the development of diagnostics and treatments to tackle emerging viral threats and neglected tropical diseases.
Who is the fund available to?
The fund will be available to all of LSTM’s partners, including research organisations in low-and-middle-income countries.
Infection Innovation Consortium (iiCON)
We have also joined the LSTM-led Infection Innovation Consortium (iiCON), alongside other core partners such as Unilever, Evotec, the Liverpool University Hospitals Foundation Trust, the University of Liverpool, and Infex Therapeutics. The aim of the £250 million programme is to accelerate the discovery and development of new therapies and innovations.
iiCON agreement
As part of this agreement, we have made our antibody humanisation platform available for iiCON and its partners to support the development of new potential treatments. The Translational Development Fund will also be available to iiCON and its collaborators.
Contact us
In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. If you would like your data to be removed, please email dataprivacy@lifearc.org.
Please see our Privacy Policy in relation to the personal data you submit to us through this page.
This site is protected by reCAPTCHA and the Google privacy policy and terms apply.
Related stories
-
News releasesLifeArc-founded RQ Bio secures £85.5 million to advance long-acting antibody for influenza prevention
Read more: LifeArc-founded RQ Bio secures £85.5 million to advance long-acting antibody for influenza prevention -
News releasesNew boost for personalised rare disease treatments as the Rare Therapies Launch Pad becomes part of LifeArc
Read more: New boost for personalised rare disease treatments as the Rare Therapies Launch Pad becomes part of LifeArc -
News releasesWorld-first gene therapy to target devastating rare immune disorder
Read more: World-first gene therapy to target devastating rare immune disorder
